Nashville, TN, April 30, 2021 – FlemingMartin is pleased to announce that Revance (NASDAQ: RVNC), an innovative biotechnology company focused on redefining the neuromodulator market through next-generation aesthetic and therapeutic offerings, has hired Helen Yu, M.D., Ph.D., as Vice President of Pharmacovigilance. Dr. Yu will strengthen and grow Revance’s Pharmacovigilance department as the Company launches and develops new products: broadening its portfolios, transforming patient experiences, and disrupting the status quo.

Dr. Yu is a hands-on leader with diverse professional experiences over her industry career, spanning both pharmacovigilance and medical affairs. Most recently, Dr. Yu held the position of Executive Director of Drug Safety at Ionis Pharmaceuticals for more than four years. Previously, she served as a Medical Director for Global Pharmacovigilance and Epidemiology at Bristol-Myers Squibb. Prior to BMS, Dr. Yu held roles of increasing responsibility in Global Safety and Medical Affairs at both Amylin Pharmaceuticals and Elan Pharmaceuticals.

Dr. Yu earned both her M.D. and M.S. in Immunology from Shanghai Jiao Tong University School of Medicine in Shanghai, China. She then received a Ph.D. in Immunology and Microbiology, as well as an M.S. in Information Technology, from Virginia Commonwealth University in Richmond, Virginia.

Revance logo 2021Revance (NASDAQ: RVNC) is a biotechnology company focused on innovative aesthetic and therapeutic offerings, as well as financial technology services for aesthetic practices. Revance has a team of motivated, talented professionals across the U.S. who collectively aim to transform patient experiences and disrupt the status quo. The Company believes in leaving bureaucracy behind, and values speed, audacity, grit, and empathy.

 

Fleming Martin Color Logo Large 72 ppiFlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms and CEOs of companies to build successful execution-focused management teams. FlemingMartin focuses on the Life Sciences, Technology, and Financial Services industries. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital.